Pharmafile Logo
Pharmafocus logo
Advanced Search

Regeneron

Showing 15 posts of 97 posts found.

sample

Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials

June 6, 2016
Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials

Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …

News
novartis_window

Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

April 4, 2016
Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …

News

Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment

April 1, 2016
Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …

News
sanofi_pasteur_scientist

Sanofi and Regeneron meet endpoint in Phase III Praluent study

March 23, 2016
Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial

Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …

News
amgen_sign_on_wall

Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …

News
sanofi_logo_on_building

Sanofi says its RA drug bested Humira in Phase III study

March 11, 2016
Medical Communications, Research and Development Humira, Regeneron, Sanofi

Sanofi and its R&D arm Regeneron Pharmaceuticals say their monoclonal antibody sarilumab outperformed AbbVie’s Humira in treating the symptoms of …

News
nice

NICE rejects cholesterol drug Praluent in draft guidance

February 8, 2016
Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol

NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …

News
FDA sign

FDA review for Sanofi and Regeneron’s biologic arthritis drug

January 8, 2016
Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab

The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …

News
eylea

Bayer, Regeneron’s Eylea gets additional EU indication

November 2, 2015
Research and Development, Sales and Marketing Bayer, Eylea, Regeneron

The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now …

News
Praluent

Sanofi and Regeneron heart drug Praluent available in UK

October 19, 2015
Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent

Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …

News
Praluent

Sanofi and Regeneron given European nod for Praluent

September 28, 2015
Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent

The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent.  The heart drug is …

News
Regeneron building

Sanofi and Regeneron in immuno-oncology push

July 28, 2015
Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1

Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …

News
Sanofi Regeneron

FDA and EMA approve heart drug Praluent

July 27, 2015
Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent

The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …

News
Logos

Praluent scores positive trial results in Japan

July 9, 2015
Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent

Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …

News
Bayer image

Bayer and Regeneron eye drug gains another indication

March 26, 2015
Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept

Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023